213745-17-6 Usage
Uses
Used in Pharmaceutical Development:
4-Chloro-7-cyclopentyl-5-iodo-7H-pyrrolo[2,3-d]pyrimidine is used as a key intermediate in the synthesis of new pharmaceuticals. Its unique structure and the presence of halogen atoms contribute to its potential as a building block for the development of novel drugs with improved bioactivity and selectivity.
Used in Organic Chemistry Research:
In the field of organic chemistry, 4-chloro-7-cyclopentyl-5-iodo-7H-pyrrolo[2,3-d]pyrimidine serves as a valuable compound for studying the reactivity and properties of pyrrolopyrimidines. Its potential applications in the synthesis of complex organic molecules and the exploration of new reaction pathways make it an important subject of research.
Used in Medicinal Chemistry:
4-Chloro-7-cyclopentyl-5-iodo-7H-pyrrolo[2,3-d]pyrimidine is used as a starting material or a scaffold in the design and synthesis of new bioactive molecules for medicinal chemistry. Its structural features and the possibility of further functionalization make it a promising candidate for the development of new therapeutic agents.
Note: The specific applications mentioned above are hypothetical and based on the general properties of pyrrolopyrimidines. The actual uses of 4-chloro-7-cyclopentyl-5-iodo-7H-pyrrolo[2,3-d]pyrimidine may vary and require further investigation and validation.
Check Digit Verification of cas no
The CAS Registry Mumber 213745-17-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,3,7,4 and 5 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 213745-17:
(8*2)+(7*1)+(6*3)+(5*7)+(4*4)+(3*5)+(2*1)+(1*7)=116
116 % 10 = 6
So 213745-17-6 is a valid CAS Registry Number.
213745-17-6Relevant articles and documents
ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY
-
Page/Page column 35, (2019/01/10)
The invention provides a series of conformationally stable and selective kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly inter
Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors
Smith, Davis E.,Marquez, Isaac,Lokensgard, Melissa E.,Rheingold, Arnold L.,Hecht, David A.,Gustafson, Jeffrey L.
supporting information, p. 11754 - 11759 (2015/10/05)
Many biologically active molecules exist as rapidly interconverting atropisomeric mixtures. Whereas one atropisomer inhibits the desired target, the other can lead to off-target effects. Herein, we study atropisomerism as a possibility to improve the sele
PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER
-
Page/Page column 38, (2010/02/11)
The invention relates to compounds of the formula (1), or a pharmaceutically acceptable salt, prodrug or hydrates thereof, wherein X, L, R1, R2, R3 and R4 are as defined herein. The invention also relates to pha